Spending Spree on Telehealth Is Winding Down
This year, funding fell from $10.5 billion in the first quarter down to the lowest funding has been at $4.6 billion today, according to a report from HealthcareDive.
Funding for digital health is decreasing back to its lowest levels since 2019. Market adjustments and inflation and interest rates may be to thank.
COVID-19 brought telehealth its biggest break in 2020 when healthcare and much of the world operated and delivered care virtually. At an average of $5.4 billion in funding in 2019, telehealth's worth skyrocketed to its highest of $16.8 billion 2021, being one of the biggest demands in healthcare.
This year, funding fell from $10.5 billion in the first quarter down to the lowest funding has been at $4.6 billion today, according to a report from HealthcareDive.
The decrease in funding is severe for clinical trials tech, telehealth and health IT, though telehealth and health IT continue to see some of the highest funding amounts overall.
According to the report, CB Insights said this year's total telehealth funding is projected to be less than half of what the sector brought in during 2021.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
ICI-Chemo Combo Delivers More Benefit Than Harm, Even for High-Risk NSCLC Patients, Study Finds
May 16th 2025Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.
Read More
